Norfloxacin

Generic Name: Norfloxacin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₈FN_₃O_₃

CAS Number: 70458-96-7

Unique Ingredient Identifier: N0F8P22L1P

Background: A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.

Indication: For the treatment of urinary tract infection

Associated Conditions: Cystitis, Gonococcal cervicitis, Infectious diarrhea, Pyelitis, Pyelonephritis, Spontaneous Bacterial Peritonitis (SBP), Traveler's Diarrhea, Urethritis gonococcal

Associated Therapies: -

Clinical Trials

Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)

Not Applicable

Not yet recruiting

Conditions: Spontaneous Bacterial Peritonitis

Interventions: Drug: Rifaximin
Drug: Norfloxacin

First Posted Date: 2024-01-10

Last Posted Date: 2024-01-10

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 280

Registration Number: NCT06199843

Locations: 🇮🇳
Dr Jaya Benjamin, New Delhi, Delhi, India

Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

Phase 3

Conditions: Spontaneous Bacterial Peritonitis

Interventions: Drug: Nitazoxanide
Drug: Norfloxacin

First Posted Date: 2021-02-10

Last Posted Date: 2021-02-10

Lead Sponsor: Tanta University

Target Recruit Count: 60

Registration Number: NCT04746937

Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Phase 3

Recruiting

Conditions: Spontaneous Bacterial Peritonitis

Interventions: Drug: Norfloxacin
Drug: Itopride

First Posted Date: 2019-11-13

Last Posted Date: 2019-11-13

Lead Sponsor: Tanta University

Target Recruit Count: 80

Registration Number: NCT04161768

Locations: 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt

Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis

Phase 3

Conditions: Spontaneous Bacterial Peritonitis

Interventions: Drug: Norfloxacin
Drug: Rifaximin

First Posted Date: 2019-11-12

Last Posted Date: 2021-02-16

Lead Sponsor: Ospedali Riuniti di Foggia

Target Recruit Count: 322

Registration Number: NCT04159870

Locations: 🇮🇹
Ospedali Riuniti Foggia, Foggia, Italy

Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis

Not Applicable

Completed

Conditions: Spontaneous Bacterial Peritonitis

Interventions: Drug: GMCSF
Drug: Norfloxacin

First Posted Date: 2018-10-11

Last Posted Date: 2019-10-24

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 120

Registration Number: NCT03702426

Locations: 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India

Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Phase 3

Conditions: Spontaneous Bacterial Peritonitis
Ascites
Liver Cirrhosis

Interventions: Drug: Rifaximin
Drug: Norfloxacin

First Posted Date: 2014-04-22

Last Posted Date: 2018-01-09

Lead Sponsor: Sherief Abd-Elsalam

Target Recruit Count: 100

Registration Number: NCT02120196

Locations: 🇪🇬
Tanta university hospital, Tanta, Egypt

Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention

Phase 4

Completed

Conditions: Adverse Reaction to Other Drugs and Medicines

Interventions: Drug: Norfloxacin
Drug: ciprofloxacin

First Posted Date: 2012-03-02

Last Posted Date: 2016-12-28

Lead Sponsor: Korea University

Target Recruit Count: 124

Registration Number: NCT01542801

Locations: 🇰🇷
Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of
🇰🇷
Kyungpuk National University Hospital, Daegu, Korea, Republic of
🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

and more 4 locations

Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)

Phase 3

Withdrawn

Conditions: Cystitis

Interventions: Drug: Cephalosporins
Drug: Norfloxacin

First Posted Date: 2012-02-06

Last Posted Date: 2015-07-27

Lead Sponsor: Eurofarma Laboratorios S.A.

Registration Number: NCT01527019

Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.

Phase 4

Terminated

Conditions: Urinary Tract Infections

Interventions: Drug: Norfloxacin
Drug: Diclofenac

First Posted Date: 2009-12-25

Last Posted Date: 2015-07-09

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 253

Registration Number: NCT01039545

Locations: 🇨🇭
Institute for Infectious Diseases, University of Berne, Berne, Switzerland

Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure

Phase 3

Terminated

Conditions: Cirrhosis

Interventions: Drug: Placebo
Drug: Norfloxacin

First Posted Date: 2009-12-23

Last Posted Date: 2015-12-09

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 291

Registration Number: NCT01037959

Locations: 🇫🇷
Assisatnce publique Hoptitaux de Paris, Clichy, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy